[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356174-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356174-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","early-stage-nonsmall-cell-lung-cancer-toward-a-risk-adaptive-paradigm-in-the-era-of-biologic-precision-review-article","Early stage nonsmall cell lung cancer - Toward a risk-adaptive paradigm in the era of biologic precision - Review article","","The clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Low-dose computed tomography screening, frequent detection of ground-glass opacities, and increasing incidence among never-smokers shift diagnosis toward earlier, potentially curable disease. Therapeutic advances include parenchyma-sparing surgery, minimally invasive digital navigation, and integration of perioperative immunotherapy and targeted agents. Liquid biopsy and other noninvasive monitoring support precision management, yet barriers remain: uncertainty in GGO handling, TNM limits for biologic heterogeneity, and access disparities. A risk-adaptive paradigm using AI-driven analytics and multi-omics aims to tailor treatment intensity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/early-stage-nonsmall-cell-lung-cancer-toward-a-risk-adaptive-paradigm-in-the-era-of-biologic-precision-review-article/356174/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/early-stage-nonsmall-cell-lung-cancer-toward-a-risk-adaptive-paradigm-in-the-era-of-biologic-precision-review-article/356174.png","ImageObject",300,407,{"name":42,"@type":43},"acoobca","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",15,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What has driven the shift toward earlier diagnosis of early stage nonsmall cell lung cancer?","Question",{"text":63,"@type":64},"Widespread low-dose computed tomography screening, increased detection of ground-glass opacities, and rising incidence among never-smokers have moved diagnosis toward earlier, potentially curable disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which therapeutic advances are highlighted for early stage NSCLC?",{"text":68,"@type":64},"Advances include parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the integration of perioperative immunotherapy with targeted agents.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is a risk-adaptive management paradigm proposed?",{"text":72,"@type":64},"The authors note barriers such as clinical uncertainty in ground-glass opacity management, TNM staging failing to reflect biologic heterogeneity, and global disparities in access to innovation. A risk-adaptive approach aims to tailor treatment intensity using AI-driven analytics and multi-omics.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356174,1790211778,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},3985747870733,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","DOI: 10. 3322/caac.70100  \nREVIEW ARTICLE  \nEarly stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision  \nChaoqi Zhang (张超奇) MD, PhD1  | Xuanyu Gu (谷炫谕) MD 1  | Pan Wang (王攀) MD 1  | Dongyu Li (李东宇) MD 1  |  \nGuochao Zhang (张国超) MD 1  | Ting Wang (王婷) MD, PhD1,2 |  \nPeng Wu (吴芃) PhD1 | Wei Rao (饶薇) MD3 | Shan Muhammad PhD1,4  | Binghua Tan (谭炳华) MD 1 | Yun Che (车云) MD, PhD1  | Mobai Zhu (朱墨白) MD 1  | Qilin Qiao (乔奇临) MD 1  | Fanbo Lai (来凡博) MD 1  | Bohui Zhao (赵博慧) MD 1  | Kailun Fei (费凯伦) MD5 | Yue Wu (吴玥) PhD6 | Zhihui Zhang (张志慧) PhD7  | Min Dai (代敏) PhD8  | Wanqing Chen (陈万青) MD, PhD9 |  \nYawei Zhang (张亚玮) PhD 10 | Nan Bi (毕楠) MD7  | Jie Wang (王洁) MD5 | Jie He (赫捷) MD, PhD1, 11, 12, 13   \nCorrespondence  \nJie He, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17, Panjiayuan Nanli, Chaoyang District, Beijing 100020, China.  \nEmail: [prof.jiehe@gmail.com](prof.jiehe@gmail.com)  \nFunding information  \nNoncommunicable Chronic Diseases-National Science and Technology Major Project, Grant/ Award Number: 2025ZD0552500; National High Level Hospital Clinical Research Funding, Grant/Award Numbers: 2025-LYZX-D-A01, LC2024A05; Beijing Municipal Science and Technology Commission, Grant/Award Number: Z221100007422011; National Natural Science Foundation of China, Grant/ Award Numbers: 82188102, 82573487; Capital’s Funds for Health Improvement and Research, Grant/Award Number: CFH2026-4- 40217; Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, Grant/ Award Number: 2025-I2M-XHXX-046  \nAbstract  \nThe clinical landscape of early stage nonsmall cell lung cancer is at transformative crossroads. Driven by the widespread adoption of low-dose computed tomography screening, the frequent detection of ground-glass opacities, and a rising incidence among never-smokers, the diagnostic center of gravity has shifted toward earlier, potentially curable disease. This shift has been accompanied by equally important therapeutic advances, including parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the transformative integration of perioperative immunotherapy and targeted agents. Concurrently, noninvasive monitoring approaches, such as liquid biopsy, have emerged as powerful tools to guide precision management. Despite this progress, substantial barriers to achieving a universal cure persist. Clinicians continue to face uncertainty in the management of ground-glass opacities, the anatomy-based TNM staging system fails to capture the biologic heterogeneity of early tumors, and global disparities in access to innovation remain unresolved. To address these challenges, the authors propose a shift toward a risk-adaptive management paradigm that harnesses artificial intelligence–driven analytics and multi-omics profiling to tailor treatment intensity according to each patient's biologic risk. Such an approach would enable appropriate escalation for highrisk individuals while permitting safe de-escalation for those at low risk. This  \n\n| The first three authors contributed equally to this article. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.\u003Cbr>© 2026 The Author(s). CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society. |\n\nCA Cancer J Clin. 2026;e70100.  \n[https://doi.org/10.3322/caac.70100](https://doi.org/10.3322/caac.70100)  \nwi[leyonlinelibrary.com/journal/caac](leyonlinelibrary.com/journal/caac)  \n1 of 32  \nholistic, lifespan-oriented strategy must be embraced to deliver equitable and durable cures f","cbCaiggwat2mvZVQ","https://ap.wps.com/l/cbCaiggwat2mvZVQ","pdf",7917859,32,"English","# Introduction\n## Epidemiology and stage migration\n## Challenges to conventional management\n# Precision care pillars\n## Screening and pathology\n## Multimodal therapy\n# Proposed risk-adaptive framework\n## AI-driven analytics and multi-omics\n## Treatment escalation and de-escalation","[{\"question\":\"What has driven the shift toward earlier diagnosis of early stage nonsmall cell lung cancer?\",\"answer\":\"Widespread low-dose computed tomography screening, increased detection of ground-glass opacities, and rising incidence among never-smokers have moved diagnosis toward earlier, potentially curable disease.\"},{\"question\":\"Which therapeutic advances are highlighted for early stage NSCLC?\",\"answer\":\"Advances include parenchyma-sparing surgical techniques, minimally invasive platforms enhanced by digital navigation, and the integration of perioperative immunotherapy with targeted agents.\"},{\"question\":\"Why is a risk-adaptive management paradigm proposed?\",\"answer\":\"The authors note barriers such as clinical uncertainty in ground-glass opacity management, TNM staging failing to reflect biologic heterogeneity, and global disparities in access to innovation. A risk-adaptive approach aims to tailor treatment intensity using AI-driven analytics and multi-omics.\"}]","Early stage nonsmall cell lung cancer - Toward a risk-adaptive paradigm in the era of biologic precision - Review article | PDF",1790123867,81,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f85d9e0641ab2f5b24ae15ddb92d090d.webp",983,1291,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/749b137829f73eb6738b3a51f7b5dc59.webp",982,1290,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b92c39c20f743844466ecfed894e27.webp",981,1289,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a53a79df465787681d014c595d672993.webp",980,1287]